



117TH CONGRESS  
2D SESSION

**S.** \_\_\_\_\_

To establish or continue a multidisciplinary research program to advance the discovery and preclinical development of medical products for priority virus families and other viral pathogens with a significant potential to cause a pandemic, and for other purposes.

---

IN THE SENATE OF THE UNITED STATES

---

Mr. BURR (for himself and Mr. HICKENLOOPER) introduced the following bill; which was read twice and referred to the Committee on

---

**A BILL**

To establish or continue a multidisciplinary research program to advance the discovery and preclinical development of medical products for priority virus families and other viral pathogens with a significant potential to cause a pandemic, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. RESEARCH CENTERS FOR PATHOGENS OF PAN-**  
4 **DEMIC CONCERN.**

5 Subpart 6 of part C of title IV of the Public Health  
6 Service Act is amended by inserting after section 447C  
7 (42 U.S.C. 285f-4) the following:

1 candidates that could be used in outpatient settings;  
2 and

3 “(4) carrying out or supporting other research  
4 related to medical products to address such patho-  
5 gens, as determined appropriate by the Director.

6 “(c) COORDINATION.—The Director of the Institute  
7 shall, as appropriate, provide for the coordination of ac-  
8 tivities among the centers described in subsection (a), in-  
9 cluding through—

10 “(1) facilitating the exchange of information  
11 and regular communication among the centers, as  
12 appropriate; and

13 “(2) requiring the periodic preparation and sub-  
14 mission to the Director of reports on the activities  
15 of each center.

16 “(d) PRIORITY.—In awarding funding through  
17 grants, contracts, or cooperative agreements under sub-  
18 section (a), the Director of the Institute shall, as appro-  
19 priate, give priority to applicants with existing frameworks  
20 and partnerships, as applicable, to support the advance-  
21 ment of such research.

22 “(e) COLLABORATION.—The Director of the Institute  
23 shall—

24 “(1) collaborate with the heads of other appro-  
25 priate Federal departments, agencies, and offices

1           (1) in paragraph (24), by striking “and” at the  
2           end;

3           (2) in paragraph (25), by striking the period  
4           and inserting a semicolon; and

5           (3) by inserting after paragraph (25) the fol-  
6           lowing:

7           “(26) shall consult with the Assistant Secretary  
8           for Preparedness and Response, the Director of the  
9           Biomedical Advanced Research and Development  
10          Authority, the Director of the Centers for Disease  
11          Control and Prevention, and the heads of other Fed-  
12          eral agencies and offices, as appropriate, regarding  
13          research needs to advance medical countermeasures  
14          to diagnose, mitigate, prevent, or treat harm from  
15          any biological agent or toxin, including emerging in-  
16          fectious diseases, chemical, radiological, or nuclear  
17          agent that may cause a public health emergency or  
18          other research needs related to emerging public  
19          health threats.”.